Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Netupitant/Palonosetron for Prevention of Nausea and Vomiting in Breast Cancer ADC Therapy
NCT07918079Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Nov 2026
- Primary completion
- Nov 2027
01
Overview
Phase 2, randomised trial of netupitant and palonosetron in nausea ((none)) and Vomiting (3 arms), sponsored by Fudan University. Primary endpoint: Percentage of Participants with No Nausea (VAS < 5 mm). Planned start Nov 2026; status: not yet recruiting.
02
Drugs
netupitantpalonosetron
03
Conditions
nausea ((none))Vomiting
Beyond the preview
Go deeper on NCT07918079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07918079.